We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App

Applied BioCode SARS-CoV-2 Assay Granted FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 19 Jun 2020
Print article
Image: BioCode SARS-CoV-2 Assay (Photo courtesy of Applied BioCode, Inc.)
Image: BioCode SARS-CoV-2 Assay (Photo courtesy of Applied BioCode, Inc.)
Applied BioCode, Inc. (Santa Fe Springs, CA, USA) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its BioCode SARS-CoV-2 Assay.

BioCode SARS-CoV-2 Assay is a CLIA high-complexity multiplex nucleic acid assay for the qualitative detection of SARS-CoV-2 nucleic acids in respiratory samples, including nasopharyngeal swabs, nasal swabs, oropharyngeal swabs and bronchoalveolar lavage, from individuals who are suspected of COVID-19 by their healthcare provider. It is designed to detect two different regions of the SARS-CoV-2 virus N gene which are also utilized by the CDC EUA assay.

The assay runs on the BioCode MDx-3000, an automated molecular diagnostic system. BioCode SARS-CoV-2 Assay can deliver up to 564 sample results in a day (188 sample results in an eight-hour shift) to help address COVID-19 testing needs. The assay can be run as an independent assay or in parallel with our FDA-cleared BioCode Respiratory Pathogen Panel for a more complete respiratory infection profile of patients.

"We are extremely pleased to provide our BioCode SARS-CoV-2 Assay with the high throughput automated MDx-3000 system to help with the fight against the COVID-19 pandemic,” said Dr. Winston Ho, Ph.D., Applied BioCode’s President. “Our automated assays can provide CLIA high complexity laboratories with the capability to perform high throughput, efficient testing to meet testing needs. Furthermore, our multiplex BioCode Respiratory Pathogen Panel offers comprehensive tests combined with flexible ordering and reporting capabilities. We are very proud of our company’s ability to respond to this crisis and are committed to provide sensitive and reliable diagnostic information to laboratorians to better manage their patients.”

Related Links:
Applied BioCode, Inc.

Print article


Molecular Diagnostics

view channel
Image: Micrograph of gold nanostar biosensors used to detect cancer-related microRNAs (Photo courtesy of Duke University School of Engineering)

Nanostar Biosensors Use Raman Scattering for Direct Detection of Cancer-Related MicroRNAs

A novel non-invasive nanoparticle-based assay detects cancer-related microRNAs without use of labels or target amplification. MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.